Sign in
Not yet taking people in United StatesEarly phase 1

hCG Treatment for Rehabilitation From a TBI

Key facts

Who runs it
VA Office of Research and Development
Where
Madison, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Early phase 1
People taking part
50 people, planned
Starts
1 Jan 2027
Expected to end
31 Dec 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Ovidrel
  • Placebo
Record updated
19 October 2026

Who can take part

Age
18 years to 65 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Subject is 1-month but < 6-month post-traumatic brain injury (TBI) with a moderate to severe traumatic brain injury (msTBI) defined as Glasgow Coma Scale (GCS) 4-12 (inclusive) at the time of the traumatic brain injury (TBI), and/or at the time of screening (Visit 1)
  • Stable doses of any medication, supplement or medical food that may affect brain function, unless deemed medically necessary by the patient's physician for optimal healthcare
  • Fluent in English
  • Reasonable expectation of availability to receive the 24-week course of therapy and be available for follow up evaluations

Who cannot take part

  • Receiving other investigational drugs within 30 d or 5 half-lives prior to randomization, whichever longer
  • Taking human chorionic gonadotropin (hCG), or any condition known to elevate human chorionic gonadotropin (hCG), active in the prior 24 months, e.g., choriocarcinoma or germ cell tumor
  • Patients with evidence of an active or previous thrombotic event
  • Renal disease; Asthma; known endocrine or germ cell tumor
  • Presence of significant systemic illness likely to interfere with participation in or completion of the study or to affect study results
  • History of deep venous thrombosis (DVT) or venous thromboembolism (VTE)
  • History of sleep apnea
  • Patients with known hypercoagulability, including cardiolipin/antiphospholipid antibody syndrome
  • Allergy or other contraindication to human chorionic gonadotropin (hCG)
  • Uncontrolled hypertension, defined as blood pressure persistently above 140 mm Hg systolic or 95 mm Hg diastolic despite antihypertensive therapy
  • History of breast or prostate cancer; sex hormone dependent tumors of the reproductive organs or accessory sex glands
  • Patients who have 6 or more symptoms for substance use disorder according to DSM-5 criteria
  • Taking other medications known to affect serum sex hormone or gonadotropin concentrations such as testosterone for hormone replacement therapy, goserelin or danazol, in the past three (3) months
  • Significantly depressed (Geriatric Depression Scale > 10)
  • Patients considered to be at risk for suicidality or homicidality according to the Columbia Suicide Severity Rating Scale (CSSRS)
  • Primary hypogonadism (unrelated to trauma)
  • Male patients with known/documented elevated PSA levels, or a PSA level of 4ng/mL at screening
  • Clinically significant peripheral edema
  • Severe symptoms of benign prostatic hyperplasia (BPH), i.e., International Prostate Symptom Score greater than or equal to 20 points
  • Uncontrolled thyroid, adrenal or pituitary dysfunction
  • An uncontrolled organic intracranial lesion such as a pituitary tumor

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

  • William S. Middleton Memorial Veterans Hospital, Madison, WIMadison, United StatesContact: Jenna W Quinto, PhDNot yet recruiting

About the trial

What the trial wants to find out

The COGNI-REHAB Trial is a single-site, phase O/I, randomized, double-blind, placebo-controlled study of human chorionic gonadotropin (hCG; choriogonadotropin alfa, Ovidrel®) in men with post-acute, moderate to severe traumatic brain injury (msTBI). Its objective is to assess the safety and efficacy of a 24-week regimen of Ovidrel (125 micrograms twice weekly) compared to placebo on treatment-emergent adverse events (TEAEs), cognitive and functional recovery, and circulating sex hormones.

The 2 groups in the trial

  • Treatment ArmTreatment being tested

    Ovidrel: 125 micrograms in 0.25 milliliters (mL) administered subcutaneously twice weekly for 24 weeks

    Treatment: Ovidrel

  • Placebo ArmPlacebo, for comparison

    Placebo: 0.25 milliliters (mL) of sterile normal saline administered subcutaneously twice weekly for 24 weeks

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Chorionic Gonadotropin to Improve Rehabilitation After Brain Injury - The COGNI-REHAB Study
Criteria questions
Built from NCT07557615, who can take part
Record updated
19 October 2026